Therefore, examining the expression of miRNAs targeted to FXYD3 and the function of p53 in resistant CRC cells should be regarded in subsequent studies to achieve a better result and overcome the drug resistance. This evidence concerns the gene FXYD3 and colorectal carcinoma.